Evolution of Randomized Trials in Advanced/Metastatic Soft Tissue Sarcoma: End Point Selection, Surrogacy, and Quality of Reporting [Sarcomas]

Conclusion In advanced STS, PFS and RR seem to be appropriate surrogates for OS. There is poor correlation between OS and both 3moPFS and 6moPFS. As such, caution is urged with the use of these as primary end points in randomized STS trials. The quality of toxicity reporting and interpretation of results is suboptimal.

http://jco.ascopubs.org/cgi/content/short/34/13/1469?rss=1

Source: Journal of Clinical Oncology - April 19, 2016 Category: Cancer & Oncology Authors: Zer, Prince, Amir, Abdul Razak Tags: Chemotherapy Sarcomas Source Type: research